Neurocrine Biosciences, Inc.  today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with ...

Neurocrine (NBIX) Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA capsules in adults with Huntington ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s flagship product, INGREZZA, is used to treat tardive dyskinesia and chorea in Huntington’s disease. The company also offers CRENESSITY, a first-in ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...

The FDA unveiled the Chemical Contaminants Transparency Tool, a searchable online database that provides a list of chemical contaminant types and levels used to evaluate possible harm in foods ...

After hours: March 19 at 4:58:49 PM EDT Loading Chart for NBIX ...

Through her unique approach to storytelling, Rachel Maddow provides in-depth reporting to illuminate the current state of political affairs and reveals the importance of transparency and ...

dot social. you can also post follow me on threads and linkedin where i post material daily. stay right where you are. the katie phang show begins right now. >> this is. >> the katie phang show live ...